Table 2.

Participant timeline

Study periods
	Form	Baselinea	Enrolment	Allocation	Intervention (8 weeks)					Follow-up
Timepoint		− T1		T0		T1	T2	T3	T4	T5	T6	T7
Time (month, weeks)		- max. 4 (w)		0 (w)	0 (w)	2 (w)	4 (w)	6 (w)	8 (w)/ 2 (m)	6 (m)	9 (m)	12 (m)
Patient information and informed consent	IC		x
Allocation				x
Demographics	TI	x
In-/exclusion criteria	TI	x
Lifetime and current diagnosis	TI	x										x
Social and role functioning	TI	x										x
Service use	TI											x
Life events	TI	x										x
General psychopathology	OS	x							x	x	x	x
Suicidality	OS	x			x	x	x	x	x	x	x	x
Subclinical symptoms	OS	x							x	x	x	x
Transdiagnostic mechanisms	OS	x							x	x	x	x
Optional qualitative interview	TI								x
Satisfaction with the intervention	OS								x
Adherence									x
Negative intervention effects	OS								x
Working alliance	OS					x	x	x	x
Therapy motivation	OS				x	x	x	x	x
Adverse events and device deficiencies	OS/TI				x	x	x	x	x	x	x	x

TI Telephone interview, OS Online survey, w Weeks, m Months

^aBaseline assessments have been approved and conducted within the EMERGE study [100]